Associations Among Gut Permeability, Inflammatory Markers, and Symptoms in Patients with Irritable Bowel Syndrome

Overview

Journal J Gastroenterol

Specialty Gastroenterology

Date 2014 Jan 18

PMID 24435814

Citations 44

Authors

Robert J Shulman

Monica E Jarrett

Kevin C Cain

Elizabeth K Broussard

Margaret M Heitkemper

Affiliations

Soon will be listed here.

Abstract

Background: Alterations in gastrointestinal (GI) permeability and immune measures are present in some patients with irritable bowel syndrome (IBS) but the relationship to symptoms is poorly defined. In adults with IBS, we compared permeability, unstimulated peripheral blood monocyte (PBMC) interleukin-10 (IL-10) levels, IBS life interference, and GI and psychological distress symptoms.

Methods: In 88 women and 18 men with IBS, GI permeability was quantitated as percent recovery of urinary sucrose and the lactulose/mannitol (L/M) ratio. IL-10 was measured in supernatants from 72-h incubated, unstimulated PBMCs. Participants completed a 4-week daily diary recording IBS life interference on daily activities and work, IBS symptoms, and psychological distress symptoms. They also completed the Brief Symptom Inventory.

Results: The L/M ratio but not percent sucrose recovery was significantly correlated with IBS interference with activities and work and retrospectively measured anxiety and depression. Unstimulated PBMC production of IL-10 correlated significantly with IBS interference with daily work, IBS symptom score, and abdominal pain. We identified a subgroup of IBS subjects with higher IL-10 and/or higher L/M ratio who had substantially higher IBS interference and IBS symptom scores.

Conclusions: Our findings suggest a distinct subgroup of IBS patients with alterations in gut barrier function. This subgroup is characterized by increased GI permeability and/or increased PBMC production of IL-10. These physiologic alterations reflect more severe IBS as measured by interference of IBS with daily activities and daily IBS symptoms.

Citing Articles

The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review.

Kasti A, Katsas K, Nikolaki M, Triantafyllou K Microorganisms. 2025; 13(1).

PMID: 39858939 PMC: 11767632. DOI: 10.3390/microorganisms13010171.

Exploring Gut Microbiota Imbalance in Irritable Bowel Syndrome: Potential Therapeutic Effects of Probiotics and Their Metabolites.

Garcia Mansilla M, Rodriguez Sojo M, Lista A, Ayala Mosqueda C, Ruiz Malagon A, Galvez J Nutrients. 2025; 17(1.

PMID: 39796588 PMC: 11723002. DOI: 10.3390/nu17010155.

Exploration of Cytokines and Microbiome Among Males and Females with Diarrhea-Predominant Irritable Bowel Syndrome.

Chen L, Plantinga A, Burr R, Cain K, Barney P, Savidge T Dig Dis Sci. 2025; .

PMID: 39779588 DOI: 10.1007/s10620-024-08836-5.

Intestinal Permeability In Subjects With Rheumatoid Arthritis: A Critical Therapeutic Priority.

Guilliams T, Weintraub J, Spar M Integr Med (Encinitas). 2024; 23(5):16-26.

PMID: 39534664 PMC: 11552960.

Intestinal Permeability, Irritable Bowel Syndrome with Constipation, and the Role of Sodium-Hydrogen Exchanger Isoform 3 (NHE3).

Lacy B, Rosenbaum D, Edelstein S, Kozuka K, Williams L, Kunkel D Clin Exp Gastroenterol. 2024; 17:173-183.

PMID: 38860153 PMC: 11164200. DOI: 10.2147/CEG.S455101.

References

Schmulson M, Pulido-London D, Rodriguez O, Morales-Rochlin N, Martinez-Garcia R, Gutierrez-Ruiz M . Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico. Am J Gastroenterol. 2012; 107(5):747-53. DOI: 10.1038/ajg.2011.484. View

Jarrett M, Cain K, Burr R, Hertig V, Rosen S, Heitkemper M . Comprehensive self-management for irritable bowel syndrome: randomized trial of in-person vs. combined in-person and telephone sessions. Am J Gastroenterol. 2009; 104(12):3004-14. PMC: 2804069. DOI: 10.1038/ajg.2009.479. View

Matricon J, Meleine M, Gelot A, Piche T, Dapoigny M, Muller E . Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther. 2012; 36(11-12):1009-31. DOI: 10.1111/apt.12080. View

Kaji I, Yasuoka Y, Karaki S, Kuwahara A . Activation of TRPA1 by luminal stimuli induces EP4-mediated anion secretion in human and rat colon. Am J Physiol Gastrointest Liver Physiol. 2011; 302(7):G690-701. DOI: 10.1152/ajpgi.00289.2011. View

Chogle A, Sztainberg M, Bass L, Youssef N, Miranda A, Nurko S . Accuracy of pain recall in children. J Pediatr Gastroenterol Nutr. 2012; 55(3):288-91. DOI: 10.1097/MPG.0b013e31824cf08a. View

Banchereau J, Pascual V, OGarra A . From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol. 2012; 13(10):925-31. PMC: 3609707. DOI: 10.1038/ni.2406. View

Barreau F, Ferrier L, Fioramonti J, Bueno L . New insights in the etiology and pathophysiology of irritable bowel syndrome: contribution of neonatal stress models. Pediatr Res. 2007; 62(3):240-5. DOI: 10.1203/PDR.0b013e3180db2949. View

Vignali D, Kuchroo V . IL-12 family cytokines: immunological playmakers. Nat Immunol. 2012; 13(8):722-8. PMC: 4158817. DOI: 10.1038/ni.2366. View

Reilly M, Zbrozek A, Dukes E . The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993; 4(5):353-65. DOI: 10.2165/00019053-199304050-00006. View

10.

Marshall J, Thabane M, Garg A, Clark W, Meddings J, Collins S . Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther. 2004; 20(11-12):1317-22. DOI: 10.1111/j.1365-2036.2004.02284.x. View

11.

Suzuki T . Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci. 2012; 70(4):631-59. PMC: 11113843. DOI: 10.1007/s00018-012-1070-x. View

12.

Hughes P, Harrington A, Castro J, Liebregts T, Adam B, Grasby D . Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes. Gut. 2012; 62(10):1456-65. DOI: 10.1136/gutjnl-2011-301856. View

13.

Ford A, Talley N . Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol. 2011; 46(4):421-31. DOI: 10.1007/s00535-011-0379-9. View

14.

Zhou Q, Zhang B, Verne G . Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain. 2009; 146(1-2):41-6. PMC: 2763174. DOI: 10.1016/j.pain.2009.06.017. View

15.

McOmber M, Ou C, Shulman R . Effects of timing, sex, and age on site-specific gastrointestinal permeability testing in children and adults. J Pediatr Gastroenterol Nutr. 2010; 50(3):269-75. PMC: 2830368. DOI: 10.1097/MPG.0b013e3181aa3aa9. View

16.

Ortiz-Lucas M, Saz-Peiro P, Sebastian-Domingo J . Irritable bowel syndrome immune hypothesis. Part one: the role of lymphocytes and mast cells. Rev Esp Enferm Dig. 2010; 102(11):637-47. DOI: 10.4321/s1130-01082010001100004. View

17.

Saulnier D, Riehle K, Mistretta T, Diaz M, Mandal D, Raza S . Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology. 2011; 141(5):1782-91. PMC: 3417828. DOI: 10.1053/j.gastro.2011.06.072. View

18.

Liebregts T, Adam B, Bredack C, Roth A, Heinzel S, Lester S . Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007; 132(3):913-20. DOI: 10.1053/j.gastro.2007.01.046. View

19.

Chang L, Adeyemo M, Karagiannides I, Karagiannidis I, Videlock E, Bowe C . Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol. 2011; 107(2):262-72. PMC: 3297737. DOI: 10.1038/ajg.2011.423. View

20.

Stasi C, Rosselli M, Bellini M, Laffi G, Milani S . Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. J Gastroenterol. 2012; 47(11):1177-85. DOI: 10.1007/s00535-012-0627-7. View